彭耀進，必威精装版app西汉姆联 ，北京幹細胞與再生醫學研究院雙聘“致一”研究員，科技倫理研究中心主任；兼任商務法務平台主任；生命科學學士、法律碩士、法學博士（Maastricht University, Netherlands）；主要研究領域包括生命科技法與倫理、知識產權與標準、科技與創新政策等；研究成果以第一作者或/和通訊作者在Nature Biotechnology, Nature Genetics, Cell Stem Cell, Protein & Cell, 《自然辯證法通訊》《國家安全研究》《中國科學院院刊》等國內外權威學術期刊發表論文40餘篇。牽頭起草製定中國首個幹細胞研究倫理規範團體標準《人幹細胞研究倫理審查技術規範》(T/CSCB 0009—2022)。主持國家級、省部級等項目多項，包括國家重點研發計劃專項子課題、中國科學院A類戰略性先導科技專項子課題、中國科協“科技治理”年度重點課題等；2021年入選“中國科學院青年創新促進會”，2021年榮獲中國細胞生物學學會幹細胞分會“幹細胞社會公益先進個人”。

生物技術法律與倫理、知識產權與標準、科技政策與管理等

教學課程

生物醫學法律與倫理（中國科學院大學，研究生課程）

1. Liang Yu, Ruohan Feng, Youhai Sun^*, Yaojin Peng*, Governance of cross-border genomic data sharing through a human-rights approach（跨境基因組數據共享的人權導向治理研究） (forthcoming)
2. Ruohan Feng, Yaojin Peng^*, Emerging Trends in Responsible Research: How China is Shaping Its Life and Health Data Governance Ecosystem （中國在生命與健康數據治理生態係統中的作用：負責任研究的新興趨勢） (forthcoming)
3. Yaojin Peng^*, Lulu Ding, Zhenyu Xiao, Moshi Song, Jianwei Lv, Guang-Hui Liu^*, Ethical Concerns in Aging Research: Perspectives of Global Frontline Researchers（衰老研究中的倫理關切：全球科技人員的視角）, SCIENCE CHINA Life Sciences, Jun 19, 2024 (IF 9.1, SCI)
4. Yaojin Peng^*, Aijin Ma, Zhenyu Xiao, et al. Technical specifications for ethics review of human stem cell research（人幹細胞研究倫理審查技術規範）. Cell Proliferation. 2023;e13556. (IF 8.755, SCI)
5. Luxia Chen, Jianchao Gao, Ruohan Feng, Yaojin Peng^*, The Variability of Judicial Decisions in the Stem Cell Industry in China（中國幹細胞領域司法判決的異質性）, Cell Stem Cell, 2023, 30(10):1294-1298. (IF 25.269, SCI)
6. Yaojin Peng^*, Lulu Ding, Moshi Song, Zhenyu Xiao, Jianwei Lv, Guang-Hui Liu^*, Acting on ethics and governance of aging research（衰老研究的倫理問題與治理框架）, Trends in Molecular Medicine, 2023, 29(6). (IF 15.272, SCI)
7. Yaojin Peng^*, Jianwei Lv, Lulu Ding, Xia Gong, Qi Zhou^*, Responsible Governance of Human Germline Genome Editing in China（中國人類生殖係基因組編輯的負責任治理）, Biology of Reproduction, 2022 May 27;ioac114. . (IF 4.285, SCI)
8. Lulu Ding, Zhenyu Xiao, Xia Gong, Yaojin Peng^*, Knowledge Graphs of Ethical Concerns of Cerebral Organoids（知識圖譜解析腦類器官倫理蘊涵）, Cell Proliferation, 2022: e13239. (IF 8.755, SCI)
9. Yaojin Peng^*, Jianwei Lv, Zhenyu Xiao, Lulu Ding, Qi Zhou^*, A framework for the responsible reform of the 14-day rule in human embryo research（人類胚胎研究“14天規則”負責任變革的框架構建）, Protein & Cell, 2022, 13(8):552–558. (IF 14.870, SCI)
10. Zhenyu Xiao, Jianwei Lv, Siqi Zhao, Rosario Isasi, Xinwei Xie, Lei Dong, Yaojin Peng^*, The Potential Effects of the United States Abortion Ruling on Global Embryo/Foetal and Stem Cell Research（美國墮胎裁決對全球胚胎/胎兒與幹細胞研究的潛在影響）, Life Medicine. 2022 Nov 18.
11. Jiani Cao, Jie Hao, Lei Wang, Yuanqing Tan, Yuchang Tian, Shiyu Li, Aijin Ma, Boqiang Fu, Jianwu Dai, Peijun Zhai, Peng Xiang, Yong Zhang, Tao Cheng^*, Yaojin Peng^*, Qi Zhou^*, Tongbiao Zhao^*. Developing standards to support the clinical translation of stem cells（幹細胞臨床轉化的標準製定框架與策略）, STEM CELLS Transl Med. 2021; 10(S2): S85- S95. (IF: 7.655, SCI)
12. Yaojin Peng^*, Xiaoru Huang, Qi Zhou^*, Ethical and Policy Considerations for Human Embryo and Stem Cell Research in China（中國人類胚胎與幹細胞研究的倫理與政策考量）, Cell Stem Cell, 2020, 27(4). (IF 25.269, SCI)
13. Jianwei Lv^#, Yeyang Su^#, Lingqiao Song, Xia Gong, Yaojin Peng^*, Stem cell ‘therapy’ advertisements in China: infodemic, regulations and recommendations（幹細胞“治療”虛假宣傳亂象解析：信息失序、監管挑戰與政策建議）, Cell Proliferation, 2020, 53(12). (IF 8.755, SCI)
14. Yaojin Peng^*, Patenting Human Embryonic Stem Cell Related Inventions in China: A Comparative Perspective（中國人類胚胎幹細胞相關發明的專利保護研究：基於比較法視角）, PhD thesis (Faculty of Law, Maastricht University, Netherlands, September 2018)
15. Yaojin Peng^*, The Patentability of Human Embryonic Stem Cell Technology in China（中國人類胚胎幹細胞技術的可專利性解析）, Nature Biotechnology, 2016, 34(1). DOI:10.1038/nbt.3417. (IF 43.113, SCI)
16. Yaojin Peng^*, The Morality and Ethics Governing CRISPR-Cas9 Patents in China（中國基因編輯專利的道德與倫理規製）, Nature Biotechnology, 2016, 34(6). DOI:10.1038/nbt.3590. (IF 43.113, SCI)
17. Yaojin Peng^*, Patent Term Extension in the Pharmaceutical Sector: An Asian Comparative Perspective（藥品專利期限延長製度探析：基於亞洲比較法視角）, in The Future of Asian Trade Deals and IP (Kung-Chung Liu ed., Hart Publishing, forthcoming in 2019).
18. Yaojin Peng, UW-Google Intermediary Liability Research Project: Privacy Protection in China（UW-Google網絡中介責任研究項目：中國隱私保護）, available at https://www.law.uw.edu/media/1404/china-intermediary-liability-of-isps-privacy.pdf.
19. Nguyen Xuan-Thao, Trademark apologetic justice: China’s trademark jurisprudence on reputational harm. in Foreign scholars on Chinese law series: intellectual property law (translated into Chinese by Yaojin Peng^*), in Intellectual Property Law of China, Encyclopedia of China Publishing House, 2018).
20. Qianwen Chen, Siqi Zhao, Yaojin Peng, Organoids: technological innovation and ethical controversies（類器官：技術創新與倫理爭議）, Synthetic Biology Journal《合成生物學》,2024, 5. DOI: 10.12211/2096-8280.2024-009.
21. ShuaiShuai Niu , Lei1 Wang, TongBiao Zhao, Yaojin Peng^*, Jie Hao^*, Challenges and opportunities in the development of standardized stem cell resource centers（幹細胞資源庫的標準化建設：挑戰和機遇）Sci Sin Vitae《中國科學：生命科學》, 2024, 54, doi: 10.1360/SSV-2024-0118. （CSCD，北大核心）
22. Jianchao Gao, Yaojin Peng, Wei Wei, Shuang Lu, Chenyan Gao, Panorama of human embryo-derived cells in biomedicine and progress in their research and regulation（人胚胎來源細胞在生物醫藥領域的應用曆史及研究和監管進展）Bulletin of Chinese Academy of Sciences《中國科學院院刊》, 2024,39(2):388-396. （CSCD，中文核心）
23. Lulu Ding, Siqi Zhao, Yaojin Peng^*, Tension between Technology and Ethics of Human-animal Chimera Research（人-動物嵌合體研究的技術-倫理張力）Studies in Science of Science 《科學學研究》, 2023.https://doi.org/10.16192/j.cnki.1003-2053.20230915.001. （CSSCI，北大核心）
24. Luxia Chen, Xinwei Xie, Zhenyu Xiao, Yaojin Peng^*, Challenges of mitochondrial replacement technology and its regulation（線粒體置換技術的挑戰及其規製），Biomedical Transformation《生物醫學轉化》, 2022,3(04):96-105. （CSCD）
25. Jianwei Lv，Yaojin Peng^*，Reconstruction on the Withdrawal of Informed Consent System for Human Biological Samples（人體生物樣本知情同意退出製度重塑），Science and Society《科學與社會》，2022,12(2):137-156.（CSSCI擴展板）
26. Yaojin Peng^*，Jianwei Lv，The challenges and solutions of the 14-day rule in human embryo research（人類胚胎研究“14天規則”的挑戰與出路）, Journal of Dialectics of Nature《自然辯證法通訊》, 2022,44(10):77-86 (CSSCI，北大核心)（被評委《自然辯證法通訊》2022年度最受歡迎的10篇論文）
27. Yaojin Peng, Qi Zhou^*，China’s Strategies for Governance of Biotechnological Changes and New Ethical Challenges（應對生物技術變革與倫理新挑戰的中國方略）, Bulletin of Chinese Academy of Sciences《中國科學院院刊》, 2021,36(11):1288-1297. （CSCD，中文核心）
28. Yaojin Peng^*, The Era of Synthetic Biology: Biosafety, Biosecurity and Governance（合成生物學時代：生物安全、生物安保與治理），Journal of International Security Studies《國際安全研究》，2020, 38(5): 29-57.（CSSCI）
29. Yaojin Peng^*, Li Wei, Ethical issues and the governance of life science and technology: A case study on human-animal chimeras（生命科技倫理問題與治理策略——以人-動物嵌合體研究為例）, Science & Technology Review（科技導報），2020, 38(5): 42-49.（CSCD，中文核心）
30. Qi Zhou^*, Yaojin Peng, The Era of Biotechnology and Biosafety（這是生物技術的時代，也是生物安全的時代）, Journal of Engineering Studies（工程研究——跨學科視野中的工程），2020, 12(1).（CSCD，中文核心）
31. Yaojin Peng^*，Designer baby: How to face it（“設計嬰兒”：我們將怎樣麵對）, Frontier Science（前沿科學）, 2019(3): 93-96.
32. Yaojin Peng^*, Intellectual Property Protection Concerning Stem Cell Research in China: Predicament and Solutions（中國幹細胞知識產權保護的困境與對策）, Chinese Bulletin of Life Science（生命科學）, 2016, 28(8).（CSCD、北大核心）
33. Yaojin Peng^*, Employees’ Invention Compensation Regime in the Netherlands and Its Enlightenment to China（荷蘭職務發明獎酬製度及其借鑒意義）, Journal of Fujian Jiangxia University（福建夏學院學報）, 2017, 7(4): 29-38.
34. Yong Wan, Jie Wang, Tianxiang He, Yaojin Peng, Zijiao Cheng, The Protection of Privacy in China（中國的隱私保護）, Journal of Shantou University （汕頭大學學報）, 2017, 33(11) .

參與的標準

1. Yu M, Lei W, Cao J, Wang L, Ma A, Zhao ZA, Yang HT, Shen Z, Lan F, Cao F, Liang P, Pei X, Xiang AP, Yu J, Zhang Y, Zhang Y, Li Q, Zhou J, Wei J, Peng Y, Zhu H, Liang L, Cao N, Fu B, Hao J, Zhao T, Hu S. Requirements for human cardiomyocytes（人類心肌細胞的規範要求）. Cell Prolif. 2022 Apr;55(4):e13150. doi: 10.1111/cpr.13150.
2. Chen X, Huang J, Wu J, Hao J, Fu B, Wang Y, Zhou B, Na T, Wei J, Zhang Y, Li Q, Hu S, Zhou J, Yu J, Wu Z, Zhu H, Cao J, Wang L, Peng Y, Liang L, Ma A, Zhang Y, Zhao T, Xiang AP. Human mesenchymal stem cells. Cell Prolif. 2022 Apr;55(4):e13141. doi: 10.1111/cpr.13141.
3. Peng Z, Wu J, Hu S, Ma A, Wang L, Cao N, Zhang Y, Li Q, Yu J, Meng S, Na T, Shi X, Li M, Liu H, Qian L, Tian E, Lin F, Cao J, Peng Y, Zhu H, Liang L, Hao J, Zhao T, Cheng X, Pan G. Requirments for primary human hepatocyte. Cell Prolif. 2022 Apr;55(4):e13147. doi: 10.1111/cpr.13147.
4. Wang L, Cao J, Peng Y, Fu B, Jin Z, Hu Y, Wu W, Xiang AP, Hu S, Yu J, Zhang Y, Wei J, Zhang Y, Li Q, Zhou J, Zhai P, Zhu H, Liang L, Ma A, Stacey G, Zhao T, Hao J. Human retinal pigment epithelial cells. Cell Prolif. 2022 Apr;55(4):e13153. doi: 10.1111/cpr.13153.
5. Nan X, Zhang B, Hao J, Yue W, Fu B, Qu M, Zhang Y, Wang H, Fang F, Wei J, Li Q, Hu S, Yu J, Gao Y, Liu Q, Cao J, Wang L, Peng Y, Zhu H, Liang L, Ma A, Zhou J, Zhao T, Pei X. Requirements for human haematopoietic stem/progenitor cells. Cell Prolif. 2022 Apr;55(4):e13152. doi: 10.1111/cpr.13152.
6. Zhang Y, Wei J, Cao J, Zhang K, Peng Y, Deng H, Kang J, Pan G, Zhang Y, Fu B, Hu S, Na J, Liu Y, Wang L, Liang L, Zhu H, Zhang Y, Jin ZB, Hao J, Ma A, Zhao T, Yu J. Requirements for human-induced pluripotent stem cells. Cell Prolif. 2022 Apr;55(4):e13182. doi: 10.1111/cpr.13182.